Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet

Passage Bio (PASG) recently gained 24.2% and has a Wall Street consensus price target of $59.25, implying a 731% upside; however, the article cautions against relying solely on price targets due to their variability and potential for bias. A more robust indicator for PASG's potential upside is the strong analyst agreement on upward earnings estimate revisions, with the Zacks Consensus EPS estimate for the current year increasing 30.3% over the past month, a trend empirically linked to near-term stock performance. This positive outlook is further supported by PASG's Zacks Rank #2 (Buy).

Analysis

Passage Bio, Inc. (PASG) has demonstrated strong recent momentum, gaining 24.2% over the past four weeks to close at $7.13. While Wall Street's mean price target of $59.25 suggests a headline-grabbing 731% upside, this figure is highly speculative and should be viewed with considerable skepticism. The underlying data reveals a profound lack of consensus among the four covering analysts, evidenced by an extremely wide target range of $10.00 to $120.00 and a high standard deviation of $46.71. A more reliable and actionable signal for PASG's near-term potential is the positive trend in its earnings estimates. The Zacks Consensus Estimate for the current year has increased by 30.3% over the last month, a move based on two upward revisions and no negative revisions. This trend, which empirical research correlates with near-term price movements, is further substantiated by the company's Zacks Rank #2 (Buy), indicating it is in the top 20% of over 4,000 ranked stocks and providing a more conclusive indicator of potential upside than the divergent price targets.

Key Decisions for Investors

• Investors should heavily discount the 731% upside implied by the mean price target, as the high standard deviation and wide range of analyst estimates signal extreme uncertainty and a lack of consensus on the stock's valuation.
• The primary bullish thesis for PASG in the near term should be based on the positive earnings estimate revisions, specifically the 30.3% increase in the consensus estimate over the past month, which is a historically stronger predictor of stock performance.
• Given the combination of positive earnings momentum and a Zacks #2 (Buy) rank, a bullish position could be considered, but investors must remain cognizant of the high volatility and valuation risk highlighted by the disparate analyst price targets.